Cargando…
Mir‐1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53
BACKGROUND: Many chemotherapy regimens are used to treat breast cancer; however, breast cancer cells often develop drug resistance that usually leads to relapse and poor prognosis. MicroRNAs (miRNAs) are short non‐coding RNA molecules that post‐transcriptionally regulate gene expression and play cru...
Autores principales: | Wang, Xinyan, Zhu, Jianwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983221/ https://www.ncbi.nlm.nih.gov/pubmed/29697201 http://dx.doi.org/10.1111/1759-7714.12607 |
Ejemplares similares
-
miR-1307-5p suppresses proliferation and tumorigenesis of bladder cancer via targeting MDM4 and the Hippo signaling pathway
por: Huang, Wei, et al.
Publicado: (2022) -
miR-1307-3p Stimulates Breast Cancer Development and Progression by Targeting SMYD4
por: Han, Sanghak, et al.
Publicado: (2019) -
The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer
por: Zhou, Yingying, et al.
Publicado: (2015) -
BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53
por: Luo, Yanwei, et al.
Publicado: (2022) -
1307. The Mycoplasma Conundrum
por: Rand, Kenneth
Publicado: (2021)